|
1
|
Kew MC: Epidemiology of chronic hepatitis
B virus infection, hepatocellular carcinoma and hepatitis B
virus-induced hepatocellular carcinoma. Pathol Biol (Paris).
58:273–277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mizuguchi Y, Takizawa T and Uchida E: Host
cellular microRNA involvement in the control of hepatitis B virus
gene expression and replication. World J Hepatol. 7:696–702. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marcucci F, Spada E, Mele A, Caserta CA
and Pulsoni A: The association of hepatitis B virus infection with
B-cell non-Hodgkin lymphoma-a review. Am J Blood Res. 2:18–28.
2012.PubMed/NCBI
|
|
4
|
Ciesek S, Helfritz FA, Lehmann U, Becker
T, Strassburg CP, Neipp M, Ciner A, Fytili P, Tillmann HL, Manns MP
and Wedemeyer H: Persistence of occult hepatitis B after removal of
the hepatitis B virus-infected liver. J Infect Dis. 197:355–360.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoffe B, Burns DK, Bhatt HS and Combes B:
Extrahepatic hepatitis B virus DNA sequences in patients with acute
hepatitis B infection. Hepatology. 12:187–192. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marcucci F and Mele A: Hepatitis viruses
and non-Hodgkin lymphoma: Epidemiology, mechanisms of
tumorigenesis, and therapeutic opportunities. Blood. 117:1782–1789.
2011. View Article : Google Scholar
|
|
7
|
Engels EA, Cho ER and Jee SH: Hepatitis B
virus infection and risk of non-Hodgkin lymphoma in South Korea: A
cohort study. Lancet Oncol. 11:827–834. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yi HZ, Chen JJ, Cen H, Yan W and Tan XH:
Association between infection of hepatitis B virus and onset risk
of B-cell non-Hodgkin's lymphoma: A systematic review and a
meta-analysis. Med Oncol. 31:842014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Galun E, Ilan Y, Livni N, Ketzinel M,
Nahor O, Pizov G, Nagler A, Eid A, Rivkind A, Laster M, et al:
Hepatitis B virus infection associated with hematopoietic tumors.
Am J Pathol. 145:1001–1007. 1994.PubMed/NCBI
|
|
10
|
Kim JH, Bang YJ, Park BJ, Yoo T, Kim CW,
Kim TY, Heo DS, Lee HS and Kim NK: Hepatitis B virus infection and
B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: A
case-control study. Jpn J Cancer Res. 93:471–477. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marcucci F, Mele A, Spada E, Candido A,
Bianco E, Pulsoni A, Chionne P, Madonna E, Cotichini R, Barbui A,
et al: High prevalence of hepatitis B virus infection in B cell
non-Hodgkin lymphoma. Haematologica. 91:554–557. 2006.PubMed/NCBI
|
|
12
|
Nath A, Agarwal R, Malhotra P and Varma S:
Prevalence of hepatitis B virus infection in non-Hodgkin's
lymphoma. A systematic review and meta-analysis. Intern Med J.
40:633–641. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bréchot C, Thiers V, Kremsdorf D, Nalpas
B, Pol S and Paterlini-Bréchot P: Persistent hepatitis B virus
infection in subjects without hepatitis B surface antigen:
Clinically significant or purely ‘occult’? Hepatology. 34:194–203.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuki N, Nagaoka T, Yamashiro M, Mochizuki
K, Kaneko A, Yamamoto K, Omura M, Hikiji K and Kato M: Long-term
histologic and virologic outcomes of acute self-limited hepatitis
B. Hepatology. 37:1172–1179. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rehermann B, Ferrari C, Pasquinelli C and
Chisari FV: The hepatitis B virus persists for decades after
patients' recovery from acute viral hepatitis despite active
maintenance of a cytotoxic T-lymphocyte response. Nat Med.
2:1104–1108. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau
JP, Teng HW, Wang WS, Chao TC, Yen CC and Chen PM: High prevalence
of occult hepatitis B virus infection in patients with B-cell
non-Hodgkin's lymphoma. Ann Hematol. 87:475–480. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rossi D, Sala L, Minisini R, Fabris C,
Falleti E, Cerri M, Burlone ME, Toniutto P, Gaidano G and Pirisi M:
Occult hepatitis B virus infection of peripheral blood mononuclear
cells among treatment-naive patients with chronic lymphocytic
leukemia. Leuk Lymphoma. 50:604–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang F, Xu RH, Han B, Shi YX, Luo HY,
Jiang WQ, Lin TY, Huang HQ, Xia ZJ and Guan ZZ: High incidence of
hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma
compared with other cancers. Cancer. 109:1360–1364. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sie L, Loong S and Tan EK: Utility of
lymphoblastoid cell lines. J Neurosci Res. 87:1953–1959. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sugimoto M, Tahara H, Ide T and Furuichi
Y: Steps involved in immortalization and tumorigenesis in human
B-lymphoblastoid cell lines transformed by Epstein-Barr virus.
Cancer Res. 64:3361–3364. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hussain T and Mulherkar R: Lymphoblastoid
cell lines: A continuous in vitro source of cells to study
carcinogen sensitivity and DNA repair. Int J Mol Cell Med. 1:75–87.
2012.PubMed/NCBI
|
|
22
|
Georgakis GV, Li Y, Rassidakis GZ,
Martinez-Valdez H, Medeiros LJ and Younes A: Inhibition of heat
shock protein 90 function by
17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells
down-regulates Akt kinase, dephosphorylates extracellular
signal-regulated kinase, and induces cell cycle arrest and cell
death. Clin Cancer Res. 12:584–590. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gui CY, Ngo L, Xu WS, Richon VM and Marks
PA: Histone deacetylase (HDAC) inhibitor activation of p21WAF1
involves changes in promoter-associated proteins, including HDAC1.
Proc Natl Acad Sci USA. 101:pp. 1241–1246. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maggio E, van den Berg A, Diepstra A,
Kluiver J, Visser L and Poppema S: Chemokines, cytokines and their
receptors in Hodgkin's lymphoma cell lines and tissues. Ann Onc. 13
Suppl 1:52–56. 2002. View Article : Google Scholar
|
|
25
|
Côté CD, Rasmussen BA, Duca FA,
Zadeh-Tahmasebi M, Baur JA, Daljeet M, Breen DM, Filippi BM and Lam
TK: Resveratrol activates duodenal Sirt1 to reverse insulin
resistance in rats through a neuronal network. Nat Med. 21:498–505.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Simms-Waldrip TR, Sunkersett G, Coughlin
LA, Savani MR, Arana C, Kim J, Kim M, Zhan X, Greenberg DE, Xie Y,
et al: Antibiotic-induced depletion of anti-inflammatory clostridia
is associated with the development of graft-versus-host disease in
pediatric stem cell transplantation patients. Biol Blood Marrow
Transplant. 23:820–829. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jain N, Oswal N, Chawla AS, Agrawal T,
Biswas M, Vrati S, Rath S, George A, Bal V and Medigeshi GR: CD8 T
cells protect adult naive mice from JEV-induced morbidity via lytic
function. PLoS Negl Trop Dis. 11:e00053292017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Feitelson MA and Duan LX: Hepatitis B
virus × antigen in the pathogenesis of chronic infections and the
development of hepatocellular carcinoma. Am J Pathol.
150:1141–1157. 1997.PubMed/NCBI
|
|
29
|
Natoli G, Avantaggiati ML, Chirillo P,
Puri PL, Ianni A, Balsano C and Levrero M: Ras- and Raf-dependent
activation of c-jun transcriptional activity by the hepatitis B
virus transactivator pX. Oncogene. 9:2837–2843. 1994.PubMed/NCBI
|
|
30
|
Wang XW, Gibson MK, Vermeulen W, Yeh H,
Forrester K, Stürzbecher HW, Hoeijmakers JH and Harris CC:
Abrogation of p53-induced apoptosis by the hepatitis B virus X
gene. Cancer Res. 55:6012–6016. 1995.PubMed/NCBI
|
|
31
|
Imai S, Armstrong CM, Kaeberlein M and
Guarente L: Transcriptional silencing and longevity protein Sir2 is
an NAD-dependent histone deacetylase. Nature. 403:795–800. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Smith JS, Brachmann CB, Celic I, Kenna MA,
Muhammad S, Starai VJ, Avalos JL, Escalante-Semerena JC, Grubmeyer
C, Wolberger C and Boeke JD: A phylogenetically conserved
NAD+-dependent protein deacetylase activity in the Sir2 protein
family. Proc Natl Acad Sci USA. 97:pp. 6658–6663. 2000; View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang H and Tindall DJ: Dynamic FoxO
transcription factors. J Cell Sci. 120:2479–2487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Salminen A, Kauppinen A, Suuronen T and
Kaarniranta K: SIRT1 longevity factor suppresses NF-kappaB-driven
immune responses: Regulation of aging via NF-kappaB acetylation?
Bioessays. 30:939–942. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van Leeuwen I and Lain S: Sirtuins and
p53. Adv Cancer Res. 102:171–195. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Deng CX: SIRT1, is it a tumor promoter or
tumor suppressor? Int J Biol Sci. 5:147–152. 2009. View Article : Google Scholar : PubMed/NCBI
|
